Brief Summary
This study will be conducted in two parts to assess the safety of AT-0174, how the treatment interacts within the body and to determine the maximum safe dosethe amount of medication taken that may be administered to patients with advancedat a late stage, far along solid cancers.
Intervention / Treatment
- AT-0174
Inclusion Criteria
- Able to understand, sign, and commit to informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. and to all study procedures
- Histological/cytological evidence of one of the following unresectable locally advanced or metastatic solid cancers:
a. Non-small cell lung carcinomacancer arising from tissues that line organs
b. Small cell lung carcinoma
c. Triple-negative breast carcinoma
d. Malignantcancerous, may grow and spread to other areas of the body melanomaa type of cancer that develops from melanocytes, which are the cells that produce pigment generally in the skin (but can develop in other areas of the body)
e. Gastric carcinoma/gastroesophageal junction carcinoma/esophageal adenocarcinomacancer arising from mucus-producing glands in organs
f. Squamous cell carcinoma of the esophagus
g. Colorectalrelating to the colon or rectum in the large bowel/intestine carcinoma
h. Pancreatic ductal adenocarcinoma
i. Epithelial ovarian carcinoma (fallopian, ovarian, primary peritoneal carcinoma)
j. Endometrial carcinoma
k. Thyroid carcinoma (non-medullary)
l. Moderate-high gradea description of how abnormal cancer cells and tissue look under a microscope when compared to healthy cells astrocytoma (oligodendroglioma, astrocytoma, or anaplastica term used to describe abnormal cancer cells that grow uncontrollably in the body and have little or no resemblence to regular cells astrocytoma [Grade 2 or 3] and glioblastoma multiforme [Grade 4])
m. Other cancers based on the Investigator’s discretion with Sponsor Medical Monitor’s approval. - Locally advanced unresectable or metastatic disease that is refractory to standard therapy, or for whom no standard therapy exists, and where standard therapy is contraindicated or has been declined by the patient
- Measurable or evaluable disease per RECIST v1.1, or Grades 2-4 astrocytoma as per RANO-HGG or RANO-LGG criteria, that was not in a prior radiation or other locally treated area unless imaging-based progression has been clearly documented following radiation or other local therapy
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer (ECOG) performance status less than or equal to 1
- Life expectancy greater than or equal to 3 months
- Adhere to contraception requirements where applicable